Metformin restrains pancreatic duodenal homeobox-1 (PDX-1) function by inhibiting ERK signaling in pancreatic ductal adenocarcinoma

G. Zhou, J. Yu, A. Wang, S. H. Liu, J. Sinnett-Smith, J. Wu, R. Sanchez, J. Nemunaitis, Camillo Ricordi, E. Rozengurt, F. C. Brunicardi

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most potent and perilous diseases known, with a median survival rate of 3-5 months due to the combination of only advanced stage diagnosis and ineffective therapeutic options. Metformin (1,1-Dimethylbiguanide hydrochloride), the leading drug used for type 2 diabetes mellitus, emerges as a potential therapy for PDAC and other human cancers. Metformin exerts its anticancer action via a variety of adenosine monophosphate (AMP)-activated protein kinase (AMPK)- dependent and/or AMPK-independent mechanisms. We present data here showing that metformin downregulated pancreatic transcription factor pancreatic duodenal homeobox-1 (PDX-1), suggesting a potential novel mechanism by which metformin exerts its anticancer action. Metformin inhibited PDX-1 expression at both protein and mRNA levels and PDX-1 transactivity as well in PDAC cells. Extracellular signal-regulated kinase (ERK) was identified as a PDX-1-interacting protein by antibody array screening in GFP-PDX-1 stable HEK293 cells. Co-transfection of ERK1 with PDX-1 resulted in an enhanced PDX-1 expression in HEK293 cells in a dose-dependent manner. Immunoprecipitation/Western blotting analysis confirmed the ERK-PDX-1 interaction in PANC-1 cells stimulated by epidermal growth factor (EGF). EGF induced an enhanced PDX-1 expression in PANC-1 cells and this stimulation was inhibited by MEK inhibitor PD0325901. Metformin inhibited EGF-stimulated PDX-1 expression with an accompanied inhibition of ERK kinase activation in PANC- 1 cells. Taken together, our studies show that PDX-1 is a potential novel target for metformin in PDAC cells and that metformin may exert its anticancer action in PDAC by down-regulating PDX-1 via a mechanism involving inhibition of ERK signaling.

Original languageEnglish (US)
Pages (from-to)83-90
Number of pages8
JournalCurrent Molecular Medicine
Volume16
Issue number1
StatePublished - Jan 1 2016

Fingerprint

Homeobox Genes
Metformin
Extracellular Signal-Regulated MAP Kinases
Adenocarcinoma
Epidermal Growth Factor
HEK293 Cells
AMP-Activated Protein Kinases
Mitogen-Activated Protein Kinase Kinases
Adenosine Monophosphate
Medical problems
Protein Kinases
Protein Array Analysis
Screening
Proteins
Transcription Factors
Phosphotransferases
Chemical activation
Immunoprecipitation
Type 2 Diabetes Mellitus
Transfection

Keywords

  • EGF
  • ERK
  • Metformin
  • PDAC
  • PDX-1
  • Signaling

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Molecular Medicine

Cite this

Zhou, G., Yu, J., Wang, A., Liu, S. H., Sinnett-Smith, J., Wu, J., ... Brunicardi, F. C. (2016). Metformin restrains pancreatic duodenal homeobox-1 (PDX-1) function by inhibiting ERK signaling in pancreatic ductal adenocarcinoma. Current Molecular Medicine, 16(1), 83-90.

Metformin restrains pancreatic duodenal homeobox-1 (PDX-1) function by inhibiting ERK signaling in pancreatic ductal adenocarcinoma. / Zhou, G.; Yu, J.; Wang, A.; Liu, S. H.; Sinnett-Smith, J.; Wu, J.; Sanchez, R.; Nemunaitis, J.; Ricordi, Camillo; Rozengurt, E.; Brunicardi, F. C.

In: Current Molecular Medicine, Vol. 16, No. 1, 01.01.2016, p. 83-90.

Research output: Contribution to journalArticle

Zhou, G, Yu, J, Wang, A, Liu, SH, Sinnett-Smith, J, Wu, J, Sanchez, R, Nemunaitis, J, Ricordi, C, Rozengurt, E & Brunicardi, FC 2016, 'Metformin restrains pancreatic duodenal homeobox-1 (PDX-1) function by inhibiting ERK signaling in pancreatic ductal adenocarcinoma', Current Molecular Medicine, vol. 16, no. 1, pp. 83-90.
Zhou, G. ; Yu, J. ; Wang, A. ; Liu, S. H. ; Sinnett-Smith, J. ; Wu, J. ; Sanchez, R. ; Nemunaitis, J. ; Ricordi, Camillo ; Rozengurt, E. ; Brunicardi, F. C. / Metformin restrains pancreatic duodenal homeobox-1 (PDX-1) function by inhibiting ERK signaling in pancreatic ductal adenocarcinoma. In: Current Molecular Medicine. 2016 ; Vol. 16, No. 1. pp. 83-90.
@article{0b7b920368964a369f66192a07b4a92e,
title = "Metformin restrains pancreatic duodenal homeobox-1 (PDX-1) function by inhibiting ERK signaling in pancreatic ductal adenocarcinoma",
abstract = "Pancreatic ductal adenocarcinoma (PDAC) is one of the most potent and perilous diseases known, with a median survival rate of 3-5 months due to the combination of only advanced stage diagnosis and ineffective therapeutic options. Metformin (1,1-Dimethylbiguanide hydrochloride), the leading drug used for type 2 diabetes mellitus, emerges as a potential therapy for PDAC and other human cancers. Metformin exerts its anticancer action via a variety of adenosine monophosphate (AMP)-activated protein kinase (AMPK)- dependent and/or AMPK-independent mechanisms. We present data here showing that metformin downregulated pancreatic transcription factor pancreatic duodenal homeobox-1 (PDX-1), suggesting a potential novel mechanism by which metformin exerts its anticancer action. Metformin inhibited PDX-1 expression at both protein and mRNA levels and PDX-1 transactivity as well in PDAC cells. Extracellular signal-regulated kinase (ERK) was identified as a PDX-1-interacting protein by antibody array screening in GFP-PDX-1 stable HEK293 cells. Co-transfection of ERK1 with PDX-1 resulted in an enhanced PDX-1 expression in HEK293 cells in a dose-dependent manner. Immunoprecipitation/Western blotting analysis confirmed the ERK-PDX-1 interaction in PANC-1 cells stimulated by epidermal growth factor (EGF). EGF induced an enhanced PDX-1 expression in PANC-1 cells and this stimulation was inhibited by MEK inhibitor PD0325901. Metformin inhibited EGF-stimulated PDX-1 expression with an accompanied inhibition of ERK kinase activation in PANC- 1 cells. Taken together, our studies show that PDX-1 is a potential novel target for metformin in PDAC cells and that metformin may exert its anticancer action in PDAC by down-regulating PDX-1 via a mechanism involving inhibition of ERK signaling.",
keywords = "EGF, ERK, Metformin, PDAC, PDX-1, Signaling",
author = "G. Zhou and J. Yu and A. Wang and Liu, {S. H.} and J. Sinnett-Smith and J. Wu and R. Sanchez and J. Nemunaitis and Camillo Ricordi and E. Rozengurt and Brunicardi, {F. C.}",
year = "2016",
month = "1",
day = "1",
language = "English (US)",
volume = "16",
pages = "83--90",
journal = "Current Molecular Medicine",
issn = "1566-5240",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Metformin restrains pancreatic duodenal homeobox-1 (PDX-1) function by inhibiting ERK signaling in pancreatic ductal adenocarcinoma

AU - Zhou, G.

AU - Yu, J.

AU - Wang, A.

AU - Liu, S. H.

AU - Sinnett-Smith, J.

AU - Wu, J.

AU - Sanchez, R.

AU - Nemunaitis, J.

AU - Ricordi, Camillo

AU - Rozengurt, E.

AU - Brunicardi, F. C.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Pancreatic ductal adenocarcinoma (PDAC) is one of the most potent and perilous diseases known, with a median survival rate of 3-5 months due to the combination of only advanced stage diagnosis and ineffective therapeutic options. Metformin (1,1-Dimethylbiguanide hydrochloride), the leading drug used for type 2 diabetes mellitus, emerges as a potential therapy for PDAC and other human cancers. Metformin exerts its anticancer action via a variety of adenosine monophosphate (AMP)-activated protein kinase (AMPK)- dependent and/or AMPK-independent mechanisms. We present data here showing that metformin downregulated pancreatic transcription factor pancreatic duodenal homeobox-1 (PDX-1), suggesting a potential novel mechanism by which metformin exerts its anticancer action. Metformin inhibited PDX-1 expression at both protein and mRNA levels and PDX-1 transactivity as well in PDAC cells. Extracellular signal-regulated kinase (ERK) was identified as a PDX-1-interacting protein by antibody array screening in GFP-PDX-1 stable HEK293 cells. Co-transfection of ERK1 with PDX-1 resulted in an enhanced PDX-1 expression in HEK293 cells in a dose-dependent manner. Immunoprecipitation/Western blotting analysis confirmed the ERK-PDX-1 interaction in PANC-1 cells stimulated by epidermal growth factor (EGF). EGF induced an enhanced PDX-1 expression in PANC-1 cells and this stimulation was inhibited by MEK inhibitor PD0325901. Metformin inhibited EGF-stimulated PDX-1 expression with an accompanied inhibition of ERK kinase activation in PANC- 1 cells. Taken together, our studies show that PDX-1 is a potential novel target for metformin in PDAC cells and that metformin may exert its anticancer action in PDAC by down-regulating PDX-1 via a mechanism involving inhibition of ERK signaling.

AB - Pancreatic ductal adenocarcinoma (PDAC) is one of the most potent and perilous diseases known, with a median survival rate of 3-5 months due to the combination of only advanced stage diagnosis and ineffective therapeutic options. Metformin (1,1-Dimethylbiguanide hydrochloride), the leading drug used for type 2 diabetes mellitus, emerges as a potential therapy for PDAC and other human cancers. Metformin exerts its anticancer action via a variety of adenosine monophosphate (AMP)-activated protein kinase (AMPK)- dependent and/or AMPK-independent mechanisms. We present data here showing that metformin downregulated pancreatic transcription factor pancreatic duodenal homeobox-1 (PDX-1), suggesting a potential novel mechanism by which metformin exerts its anticancer action. Metformin inhibited PDX-1 expression at both protein and mRNA levels and PDX-1 transactivity as well in PDAC cells. Extracellular signal-regulated kinase (ERK) was identified as a PDX-1-interacting protein by antibody array screening in GFP-PDX-1 stable HEK293 cells. Co-transfection of ERK1 with PDX-1 resulted in an enhanced PDX-1 expression in HEK293 cells in a dose-dependent manner. Immunoprecipitation/Western blotting analysis confirmed the ERK-PDX-1 interaction in PANC-1 cells stimulated by epidermal growth factor (EGF). EGF induced an enhanced PDX-1 expression in PANC-1 cells and this stimulation was inhibited by MEK inhibitor PD0325901. Metformin inhibited EGF-stimulated PDX-1 expression with an accompanied inhibition of ERK kinase activation in PANC- 1 cells. Taken together, our studies show that PDX-1 is a potential novel target for metformin in PDAC cells and that metformin may exert its anticancer action in PDAC by down-regulating PDX-1 via a mechanism involving inhibition of ERK signaling.

KW - EGF

KW - ERK

KW - Metformin

KW - PDAC

KW - PDX-1

KW - Signaling

UR - http://www.scopus.com/inward/record.url?scp=84959323795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959323795&partnerID=8YFLogxK

M3 - Article

C2 - 26695692

AN - SCOPUS:84959323795

VL - 16

SP - 83

EP - 90

JO - Current Molecular Medicine

JF - Current Molecular Medicine

SN - 1566-5240

IS - 1

ER -